207 related articles for article (PubMed ID: 17387702)
1. Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.
Turello R; Rentsch K; Di Paolo E; Popovic MB
Pediatr Blood Cancer; 2008 Jan; 50(1):154-6. PubMed ID: 17387702
[TBL] [Abstract][Full Text] [Related]
2. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
[TBL] [Abstract][Full Text] [Related]
3. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.
van Kooten Niekerk PB; Schmiegelow K; Schroeder H
Eur J Haematol; 2008 Nov; 81(5):391-8. PubMed ID: 18691257
[TBL] [Abstract][Full Text] [Related]
4. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
Seidemann K; Book M; Zimmermann M; Meyer U; Welte K; Stanulla M; Reiter A
Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
[TBL] [Abstract][Full Text] [Related]
5. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
6. Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism.
Strunk T; Gottschalk S; Goepel W; Bucsky P; Schultz C
Med Pediatr Oncol; 2003 Jan; 40(1):48-50. PubMed ID: 12426687
[No Abstract] [Full Text] [Related]
7. Methylenetetrahydrofolate reductase gene polymorphism and glucocorticoid intake in children with ALL and aseptic osteonecrosis.
Bernbeck B; Mauz-Körholz C; Zotz RB; Göbel U
Klin Padiatr; 2003; 215(6):327-31. PubMed ID: 14677097
[TBL] [Abstract][Full Text] [Related]
8. The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients.
Lambrecht L; Sleurs C; Labarque V; Dhooge C; Laenen A; Sinnaeve F; Renard M; Uyttebroeck A
Pharmacogenomics; 2017 Jun; 18(8):787-795. PubMed ID: 28592186
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia].
Zheng MM; Yue LJ; Chen XW; Wen FQ; Li CG; Yang CL; Xie C; Ding H
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Mar; 15(3):201-6. PubMed ID: 23498762
[TBL] [Abstract][Full Text] [Related]
10. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity.
Haase R; Elsner K; Merkel N; Stiefel M; Mauz-Körholz C; Kramm CM; Körholz D
Klin Padiatr; 2012 Apr; 224(3):156-9. PubMed ID: 22513795
[TBL] [Abstract][Full Text] [Related]
11. [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].
Cózar Olmo JA; Martínez Colmenero C; Peláez Pleguezuelos I; Leiva Gea I; López García AB; de la Cruz Moreno J
An Pediatr (Barc); 2009 Sep; 71(3):230-4. PubMed ID: 19617010
[TBL] [Abstract][Full Text] [Related]
12. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
[TBL] [Abstract][Full Text] [Related]
13. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
14. Managing reduced methotrexate clearance in a patient with a heterozygous methylenetetrahydrofolate reductase gene polymorphism.
Gammon DC; Bhatt MS; Patel B; Anderson M; Van Horn A; Glantz MJ
J Oncol Pharm Pract; 2008 Sep; 14(3):153-6. PubMed ID: 18719070
[TBL] [Abstract][Full Text] [Related]
15. Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity via direct endothelial injury.
Mahadeo KM; Dhall G; Panigrahy A; Lastra C; Ettinger LJ
Pediatr Hematol Oncol; 2010 Feb; 27(1):46-52. PubMed ID: 20121554
[TBL] [Abstract][Full Text] [Related]
16. [Effect of GSTP1 and MTHFR Gene Polymorphism on Side Effects of HD-MTX in ALL Children].
Li F; Yin DD; Zhou XL; Ma JM; Guo HM; Meng L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):723-728. PubMed ID: 28641625
[TBL] [Abstract][Full Text] [Related]
17. Significant impact of MTHFR C677T polymorphism on plasma homovanillic acid (HVA) levels among alcohol-dependent patients.
Lutz UC; Batra A; Wiatr G; Machicao F; Kolb W; Maurer S; Buchkremer G; Köhnke MD
Addict Biol; 2007 Mar; 12(1):100-5. PubMed ID: 17407503
[TBL] [Abstract][Full Text] [Related]
18. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
Salazar J; Altés A; del Río E; Estella J; Rives S; Tasso M; Navajas A; Molina J; Villa M; Vivanco JL; Torrent M; Baiget M; Badell I
Pharmacogenomics J; 2012 Oct; 12(5):379-85. PubMed ID: 21747412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
